Recovering Zimbabwe offers growth opportunities for Pharma, says Frost & Sullivan

Recovery from a decade-long economic contraction has been the main factor behind the growth experienced in Zimbabwe's pharmaceutical sector in the last two years. A new coalition government and subsequent macro-economic stabilization have brought renewed optimism and spurred demand in healthcare markets. This is driving the uptake of drugs - a trend that is expected to remain robust in the future with the increasing availability of low-cost generic drugs.

A new analysis from Frost & Sullivan, Healthcare Overview in Zimbabwe, finds that the pharmaceutical market in Zimbabwe earned revenues of $200 million in 2009 and estimates this to reach $370.6 million in 2016.

“A recovering economy, which has brought price stability and rising incomes, is behind the increase in expenditure," notes Frost & Sullivan health care research analyst Ishe Zingoni, adding “The increased availability of low-cost generic drugs, paralleled by the rising incidence of infectious diseases in the country, will boost pharmaceutical market development."